Premium
Early mixed chimerism‐based preemptive immunotherapy in children undergoing allogeneic hematopoietic stem cell transplantation for acute leukemia
Author(s) -
Horn Biljana,
Wahlstrom Justin T.,
Melton Alexis,
Liou Angela,
OuacheeChardin Marie,
Sunkersett Gauri,
Willert Jennifer,
Hwang Jimmy,
ExposeSpencer Jueleah,
Cowan Mort C.,
Facchino Janelle,
Dvorak Christopher C.
Publication year - 2017
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.26464
Subject(s) - medicine , hematopoietic stem cell transplantation , immunotherapy , stem cell , transplantation , leukemia , haematopoiesis , immunology , oncology , immune system , genetics , biology
This retrospective analysis comprises 10‐year experience with early posttransplant mixed chimerism‐based preemptive intervention. Out of 104 patients, 51 received preemptive immunotherapy. Their outcomes were similar to patients achieving full donor chimerism spontaneously. Among patients receiving intervention, 5‐year event‐free survival was identical in patients with and without pretransplant residual disease, respectively (68% [95% confidence interval (CI) 38–98%] vs. 69% [95% CI 54–85%] log–rank = 0.4). In patients who received preemptive immunotherapy, chimerism status and residual disease prior to transplant were no longer predictors of poor outcome; however, 41% of the patients with residual disease prior to transplant relapsed early and did not benefit from this strategy.